In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Colorectal cancer screening tests are carried to monitor bowel health of at-risk individuals, typically the elderly, in order to be able to detect and treat colorectal cancer in a timely manner. GlobalData uses proprietary data and analytics to provide a comprehensive report on the colorectal cancer screening tests market in the UK. Buy the latest report here.

In 2022, GlobalData’s Market Model methodology determined that the leading player in the colorectal cancer screening tests market in the UK was Alfresa Pharma followed by Danaher, Eiken Chemical, Epigenomics, Hemosure, Medline Industries, Quidelortho, Sekisui Diagnostics, Sentinel CH. and Showa Denko Materials.

Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.

This Colorectal cancer screening testing market includes sub-segments Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits, and Other Colorectal Cancer Screening Tests.

The colorectal cancer screening tests market in the UK can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.

For the latest analysis of the market size colorectal cancer screening tests in the UK, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.